To Stop or Not to Stop Aspirin Before Intermediate Risk Noncardiac Surgery

In a randomized trial, continued aspirin in the perioperative period did not affect ischemic and major bleeding endpoints, although these patients had more minor bleeding events.

The effect of perioperative aspirin monotherapy on ischemic and bleeding events in patients with coronary drug-eluting stents (DES) is not known. In the multinational, open-label ASSURE DES trial, 926 patients who had undergone percutaneous coronary intervention with DES placement >1 year prior and were scheduled for low-to-intermediate risk elective, noncardiac surgery were randomized to either continue/switch to aspirin monotherapy (100 mg daily) throughout the perioperative period or stop all antiplatelet agents 5 days before surgery and restart them within 48 hours after surgery. The primary outcome was a composite of death, myocardial infarction, stent thrombosis, or stroke from 5 days before to 30 days after surgery. Major and minor b…

Reviewing Author

Shea E. Hogan, MD, MSCS, FACC, FSCAI, FSVM

Disclosures

Editorial BoardsVascular Medicine

Shea E. Hogan, MD, MSCS, FACC, FSCAI, FSVM

Disclosures

Editorial BoardsVascular Medicine

To Stop or Not to Stop Aspirin Before Intermediate Risk Noncardiac Surgery

Topics

Reviewing Author